Today: 30 June 2026
Snowflake stock snaps back with 7% jump — what to watch before Monday
8 February 2026
1 min read

Snowflake stock snaps back with 7% jump — what to watch before Monday

NEW YORK, Feb 8, 2026, 05:10 EST — Market closed.

  • Snowflake finished Friday’s session 7.5% higher, closing at $168.43.
  • Tech stocks snapped back late in the week, bouncing after a shaky run for “AI” trades.
  • Director Michael L. Speiser offloaded 50,741 shares on Feb. 6, according to a filing, with the sale executed as part of a pre-set trading plan.

Snowflake Inc (SNOW) popped 7.5% Friday, closing at $168.43 after reaching $170.40 earlier in the day. The stock heads into Monday looking to keep that bounce intact.

Investors are getting pickier about which firms actually benefit from the artificial intelligence spending surge—and which ones might end up on the wrong side of it. “The market is no longer tolerating spending for spending’s sake,” Mark Hawtin, head of global equities at Liontrust, said, as traders scrutinize the returns from increased AI-driven capital expenditure, or capex. Reuters

Stocks bounced back across the board Friday, pushing the Dow past the 50,000 mark for the first time. Chipmakers rallied—investors see them as key players set to gain from growing AI data-center budgets—even as a few of the tech heavyweights faltered. “There is real demand for AI products and a floor where buyers step in after selloffs,” said Ross Mayfield, investment strategy analyst at Baird. Reuters

Snowflake’s shares have effectively become a stand-in for investor mood around AI-linked enterprise software. This corner of the market has been on edge over competition, pricing risks, and the question of whether pouring more money into AI will actually deliver better profits.

Snowflake director Michael L. Speiser unloaded 50,741 shares on Feb. 6, according to a Friday regulatory filing. The sales, which included transactions via trusts and partnerships, were carried out under a 10b5-1 trading plan, set up ahead of time.

Snowflake’s push to become the go-to “data layer” for AI is heating up. On Feb. 2, the company announced a $200 million partnership with OpenAI to embed advanced models and AI agents into its offerings. The deal lands as Databricks, a major competitor, keeps ramping up its own efforts. Reuters

Even so, a big snapback like this hardly closes the argument. Should traders keep shifting into hardware suppliers and shy from software names they view as riskier, Snowflake might just lose ground again—and fast—especially with few obvious triggers.

Traders will be eyeing whether Friday’s action draws in more buyers once the regular session starts up again, or if enthusiasm fizzles as the market takes a closer look at AI spending’s price tag and the threat of margin pressure for software.

Looking ahead, Snowflake’s next major event lands after the U.S. close on Feb. 25, when it’s set to roll out fourth-quarter and full-year results for fiscal 2026. The company has a conference call lined up that same day.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Confluent stock edges higher as IBM deal vote nears after fresh merger filing
Previous Story

Confluent stock edges higher as IBM deal vote nears after fresh merger filing

US Economic Calendar Today: Stock Futures Hold Steady as Traders Eye Fed Speeches, Treasury Buyback and Delayed Jobs Data
Next Story

US Economic Calendar Today: Stock Futures Hold Steady as Traders Eye Fed Speeches, Treasury Buyback and Delayed Jobs Data

Go toTop